Outlook Therapeutics, Inc. (OTLK)
Market Cap | 34.06M |
Revenue (ttm) | n/a |
Net Income (ttm) | -94.05M |
Shares Out | 23.66M |
EPS (ttm) | -5.93 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 706,023 |
Open | 1.370 |
Previous Close | 1.390 |
Day's Range | 1.336 - 1.470 |
52-Week Range | 0.870 - 12.850 |
Beta | 0.51 |
Analysts | Strong Buy |
Price Target | 40.57 (+2,717.36%) |
Earnings Date | Feb 12, 2025 |
About OTLK
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The compa... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for OTLK stock is "Strong Buy." The 12-month stock price forecast is $40.57, which is an increase of 2,717.36% from the latest price.
News
Outlook Therapeutics® Streamlines Operations
ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea...
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of w...
Outlook Therapeutics® Announces Executive Leadership Transition
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea...
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
Outlook Therapeutics Inc. OTLK revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients.
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea...
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET Live video webcast with Russell Trenary, President and CEO of Outlook Thera...
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
Webcast replay of fireside chat now available
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom e...
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom e...
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles
Outlook Therapeutics faces liquidity issues and delays in FDA approval for its Wet AMD therapy, leading to a downgrade from Strong Buy to Buy. The potential blockbuster market for LYTENAVA in treating...
Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript
Outlook Therapeutics, Inc. Q3 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Jenene Thomas - JTC Team, LLC, Investor Relations Russell Trenary - President and Chief Exec...
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized u...
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-v...
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized u...
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
Company to participate in a fireside chat on Monday, August 5 th at 8:00 AM ET
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
ISELIN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-v...
Outlook Therapeutics: Worth A Good Strong Look After CRL
Outlook Therapeutics received a Complete Response Letter from the FDA in August 2023, causing a 74% drop in share price. Following a Type A meeting with the FDA in November 2023, Outlook agreed to con...
Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market
Outlook Therapeutics is resubmitting a BLA for ONS-5010 by 2024, with top-line data expected in Q4, 2024. ONS-5010 received European Commission Marketing Authorization for treating wet AMD in May 2024...
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series
Live webcast on Thursday, June 13th at 4:00 PM ET FRENCHTOWN, NJ / ACCESSWIRE / June 12, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announc...
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizum...
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Watch the "What This Means" video here Outlook CEO, Russ Trenary underscores that LYTENAVA™ (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commissio...
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
ISELIN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizuma...
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Q2 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Russell Trenary - President & CEO Lawrence Ken...
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
ISELIN, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalm...